Follow the Dianthus Therapeutics, Inc. /DE/ share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €5.9bn. The latest transaction was disclosed on 3 September 2026 (Levée d'options). Among the most active insiders: Savitz Ryan. The full history is accessible without an account.
77
Insider Decl.
n/a
Thresholds
€1m
5 ops.
Buy Volume
€33m
40 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Dianthus Therapeutics, Inc. /DE/ Strong Buy (bullish), based on 13 analysts. Average price target: US$137.62.
47Σ signal
Buys €1m€33m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
2,777 shares@ US$18.360.0008% mcap5.2% of flowCommon StockSEC:0001688199-26-000004:0
25 of 77 declarations
Acerca de Dianthus Therapeutics, Inc. /DE/
Dianthus Therapeutics, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias innovadoras para el tratamiento de enfermedades autoinmunes. Cotiza en NASDAQ bajo el ticker DE.